Detalhe da pesquisa
1.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med
; 390(6): 497-509, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324483
2.
A global action agenda for turning the tide on fatty liver disease.
Hepatology
; 79(2): 502-523, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540183
3.
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
J Hepatol
; 80(5): 694-701, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286339
4.
Assessment of fatigue and its impact in chronic liver disease.
J Hepatol
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670320
5.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol
; 80(3): 419-430, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984709
6.
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Clin Gastroenterol Hepatol
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521116
7.
Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States.
Am J Gastroenterol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477467
8.
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.
J Intern Med
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38738988
9.
The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
J Viral Hepat
; 31(4): 181-188, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38158773
10.
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
J Viral Hepat
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622910
11.
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Hepatology
; 77(4): 1335-1347, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626630
12.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology
; 78(6): 1966-1986, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363821
13.
Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa.
Liver Int
; 44(4): 1061-1070, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305642
14.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Ann Hepatol
; 29(1): 101133, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364816
15.
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.
Diabetes Spectr
; 37(1): 9-19, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385101
16.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Gut
; 72(3): 581-589, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750244
17.
How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
Semin Liver Dis
; 43(2): 142-148, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414024
18.
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
J Hepatol
; 79(1): 209-217, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740046
19.
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
J Hepatol
; 78(2): 247-259, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375686
20.
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
J Hepatol
; 79(5): 1110-1120, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517454